Galena Biopharma Incorporated (NASDAQ:GALE) Shorted Shares Decreased By 2.67%

January 19, 2018 - By Nellie Frank

 Galena Biopharma Incorporated (NASDAQ:GALE) Shorted Shares Decreased By 2.67%

The stock of Galena Biopharma Incorporated (NASDAQ:GALE) registered a decrease of 2.67% in short interest. GALE’s total short interest was 3.69 million shares in January as published by FINRA. Its down 2.67% from 3.79M shares, reported previously. With 361,800 shares average volume, it will take short sellers 10 days to cover their GALE’s short positions. The short interest to Galena Biopharma Incorporated’s float is 13.49%.

The stock decreased 5.11% or $0.014 during the last trading session, reaching $0.262. About 20.37 million shares traded or 2564.72% up from the average. Galena Biopharma, Inc. (NASDAQ:GALE) has declined 98.04% since January 19, 2017 and is downtrending. It has underperformed by 114.74% the S&P500.

Galena Biopharma, Inc., a biopharmaceutical company, develops hematology and oncology therapeutics that address unmet medical needs. The company has market cap of $399,225. The firm develops GALE-401 , which completed Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. It currently has negative earnings. It also develops NeuVax (nelipepimut-S), which is in Phase IIb clinical trial in combination with trastuzumab for HER2 1+ and 2+ node positive and high-risk node negative breast cancer patients; Phase II clinical trial in combination with trastuzumab for HER2 3+ breast cancer patients; Phase II clinical trial for women with ductal carcinoma in situ of the breast; and Phase II clinical trial for patients with gastric cancer.

Galena Biopharma, Inc. (NASDAQ:GALE) Ratings Coverage

Among 7 analysts covering Galena Biopharma (NASDAQ:GALE), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Galena Biopharma had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The company was downgraded on Thursday, February 2 by Maxim Group. The firm has “Buy” rating by TH Capital given on Tuesday, November 10. The stock of Galena Biopharma, Inc. (NASDAQ:GALE) earned “Hold” rating by Cantor Fitzgerald on Tuesday, December 8. The rating was downgraded by FBR Capital to “Mkt Perform” on Monday, February 6. Roth Capital maintained the stock with “Buy” rating in Tuesday, November 10 report. The firm earned “Buy” rating on Friday, December 2 by Maxim Group. The rating was upgraded by Oppenheimer to “Outperform” on Thursday, November 12. The firm has “Outperform” rating by FBR Capital given on Friday, July 22. The firm has “Market Perform” rating by Raymond James given on Wednesday, June 29. The firm earned “Outperform” rating on Wednesday, September 9 by Raymond James.

More notable recent Galena Biopharma, Inc. (NASDAQ:GALE) news were published by: Globenewswire.com which released: “Galena Biopharma Enters into Merger Agreement with SELLAS Life Sciences Group” on August 08, 2017, also Reuters.com with their article: “BRIEF-Galena Biopharma Stockholders Approve Business Combination With Sellas …” published on December 29, 2017, Seekingalpha.com published: “Galena Biopharma (GALE) Discusses Galena Biopharma and SELLAS Life Sciences …” on August 11, 2017. More interesting news about Galena Biopharma, Inc. (NASDAQ:GALE) were released by: Seekingalpha.com and their article: “No Reasonable Path Forward For Galena Shareholders – Avoid” published on February 08, 2017 as well as Globenewswire.com‘s news article titled: “Galena Biopharma, Inc. Stockholders Approve Business Combination with SELLAS …” with publication date: December 29, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.